In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Givaudan

This article was originally published in The Rose Sheet

Executive Summary

First quarter fragrance sales decline 1.8% in Swiss Francs, or .3% in local currencies to $214.5 mil. (1 CHF=$0.77) due to discontinued sales of commodity ingredients, firm reports. Fine fragrances, however, experienced double-digit growth in local currencies driven by the launches of several prestige fragrances. Total sales in the quarter grew 2.4% in Swiss Francs, or 4.1% in local currencies, to $540.5 mil. Givaudan will continue to focus on developing proprietary fragrance ingredients this year, the company said during its annual investor meeting April 8. Among the exclusive ingredients Givaudan plans to launch is Toscanol, a replacement for Estragole, which has been found to be a naturally occurring genotoxic carcinogen. The company also will introduce Javanol, a sandalwood odorant at the World Perfumery Congress June 1-5 in Cannes, France, according to Givaudan Head of Fragrance Chemistry Markus Gautschi...

You may also be interested in...



Dr Reddy’s Posts Surprise Q3 Loss With NuvaRing Write-Off

Dr Reddy’s Laboratories reported an unexpected third-quarter consolidated net loss after taking a $156m charge related to its generic version of the NuvaRing contraceptive. However, the company’s shares jumped on a robust underlying performance that was praised by analysts.

Philips Delivers On Aim To Focus Exclusively On Health And Healthtech

Royal Philips is planning to sell its domestic appliance business to better focus on its strategic aims in health technology. The group made the announcement as it unveiled 2019 sales up 4.5% on a comparable basis.

Why Reviewing MDR Grace Period Interpretation Is Only Way To Stop Threat To Device Availability

With just under 120 days until the full application of the EU’s Medical Device Regulation, and fears growing of the loss of products seen as non-compliant, the EU medtech industry has identified a way of broadening the application of the “grace period.” It is a legal way of addressing the potential loss of tens of thousands of products come 26 May, says MedTech Europe’s Oliver Bisazza.

UsernamePublicRestriction

Register

RS012056

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel